Received Jun 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | H97H2 | — |
Shingrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 77-year-old male patient who received Herpes zoster (Shingrix) (batch number H97H2, expiry date 29-MAR-2027) for prophylaxis. Previously administered products included Shingrix (patient received a first dose of Shingrix back in September 21, 2018). On 08-APR-2025, the patient received the 2nd dose of Shingrix. On 08-APR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 10-JUN-2025 Other HCP reported that a patient received a first dose of Shingrix back in September 21, 2018 and then a second dose was given April 8, 2025, which led to drug dose administration interval too long. This case linked with US2025072149 reported by same reporter.; Sender's Comments: US-GSK-US2025072149:case created for husband and wife